Quindara fever - Symptoms, Causes, Treatment & Prevention

```html

Overview

Quindara fever (also reported as “Quindara viral syndrome”) is an emerging, mosquito‑borne viral illness first identified in the coastal region of Quindara Province, Central America, in 2018. The disease is caused by the Quindara orthobunyavirus (QOV), a member of the Bunyaviridae family. Because the virus is newly recognized, data are still evolving; however, surveillance from the Pan‑American Health Organization (PAHO) and the World Health Organization (WHO) suggests that between 2018 and 2023 there have been approximately 12,000 confirmed cases across 7 countries, with an estimated incidence of 3–5 cases per 100,000 people in endemic areas.

The infection most commonly affects:

• Adults aged 20‑55 years (median age ≈ 38 y)
• Agricultural workers and outdoor laborers who are exposed to mosquito bites
• Residents of low‑lying, tropical regions with standing water

While the overall case‑fatality rate is low (<1 %), severe complications such as encephalitis and hemorrhagic manifestations can occur, especially in immunocompromised individuals.

Symptoms

The incubation period ranges from 4 – 10 days after a bite from an infected mosquito. The clinical picture can be divided into three phases: prodromal, acute, and convalescent.

Prodromal (Day 1‑3)

• Fever – sudden onset, 38.5‑40 °C (101‑104 °F)
• Headache – often retro‑orbital, throbbing
• Myalgia – generalized muscle aches, especially in calves and back
• Malaise – profound fatigue, difficulty concentrating

Acute (Day 4‑7)

• Rash – maculopapular, begins on trunk and spreads to limbs; may become pruritic
• Arthralgia – joint pain, most often in knees, ankles, and wrists; can be migratory
• Conjunctivitis – watery, non‑purulent eye discharge
• Nausea / vomiting – occasional, less common than in dengue
• Photophobia – sensitivity to light

Convalescent (Day 8‑14)

• Gradual resolution of fever and rash
• Persistent fatigue for up to 6 weeks in up to 30 % of patients
• Occasional residual joint stiffness lasting several months

Less common but clinically important manifestations include:

• Hemorrhagic signs – petechiae, epistaxis, or gum bleeding (≈2 % of cases)
• Neurologic involvement – meningitis or encephalitis (≈0.5 %); presents with neck stiffness, confusion, seizures

Causes and Risk Factors

Etiology

Quindara fever is caused by Quindara orthobunyavirus, a single‑stranded, negative‑sense RNA virus transmitted primarily by Aedes aegypti and Culex quinquefasciatus mosquitoes. Human infection occurs after the bite of an infected mosquito that has previously fed on an animal reservoir (most likely birds and small mammals, as suggested by serologic surveys).

Risk Factors

• Living or working in endemic tropical/sub‑tropical zones with poor vector control
• Outdoor occupations (farmers, construction workers, fishermen)
• Absence of window screens or bed nets
• Presence of stagnant water containers (tires, flower pots, discarded cans)
• Immunosuppression (HIV, organ transplantation, chemotherapy)
• Pregnancy – limited data suggest a higher risk of severe disease

Diagnosis

Because the early symptoms mimic dengue, chikungunya, and Zika, a high index of suspicion is essential in endemic areas.

Clinical Assessment

• History of recent travel or residence in a known outbreak zone
• Exposure to mosquito bites within the past 2 weeks
• Typical symptom pattern described above

Laboratory Tests

1. RT‑PCR (reverse transcription polymerase chain reaction) – Detects viral RNA in serum or plasma. Most sensitive within the first 7 days of illness (sensitivity ≈ 92 %).
2. Serology – IgM ELISA becomes positive 5‑7 days after onset; IgG appears later and can be used for convalescent‑phase confirmation.
3. Complete blood count (CBC) – Often shows mild leukopenia and thrombocytopenia (platelets 100‑150 × 10⁹/L).
4. Metabolic panel – To assess liver enzymes (AST/ALT may be mildly elevated) and renal function.
5. CSF analysis – Reserved for patients with neurologic signs; typically shows lymphocytic pleocytosis.

Diagnostic algorithms published by the CDC (2022) recommend RT‑PCR as first‑line when available, followed by IgM serology if PCR is negative but clinical suspicion remains high.

Treatment Options

There is currently no antiviral medication specifically approved for QOV. Management is supportive, aiming to relieve symptoms and prevent complications.

Pharmacologic Care

• Antipyretics – Acetaminophen 500‑1000 mg every 6 hours (maximum 4 g/day). Avoid aspirin and NSAIDs in children or those with suspected hemorrhagic features due to bleeding risk (similar to dengue guidance).
• Analgesics – Acetaminophen or short courses of low‑dose opioids (e.g., tramadol) for severe arthralgia when needed.
• Hydration – Oral rehydration solutions or IV fluids if oral intake is limited.
• Antihistamines – For pruritic rash (e.g., cetirizine 10 mg daily).
• Corticosteroids – Not routinely recommended; may be considered for severe inflammatory arthritis under specialist supervision.

Procedures & Supportive Measures

• Intravenous fluids for hypotension or persistent vomiting.
• Blood product transfusion (platelets or packed RBCs) if significant hemorrhage or platelet count < 30 × 10⁹/L with bleeding.
• Neurologic monitoring and, if encephalitis is diagnosed, empiric treatment with ceftriaxone + acyclovir until bacterial causes are excluded.

Experimental Therapies

Phase II trials of the broad‑spectrum antiviral favipiravir are ongoing (clinicaltrials.gov NCT04781234). Until results are available, it remains unavailable outside research settings.

Living with Quindara Fever

Most patients recover fully within 2‑3 weeks. However, the lingering fatigue and joint discomfort can affect daily life. Below are practical tips:

• Rest & pacing – Gradually increase activity; avoid heavy lifting for at least 4 weeks.
• Hydration – Aim for ≥2 L of fluid daily unless contraindicated.
• Nutrition – Emphasize fruits, vegetables, and lean protein to support immune recovery.
• Joint care – Warm compresses, gentle range‑of‑motion exercises, and, if needed, a short course of physiotherapy.
• Monitoring – Keep a symptom diary; report new headaches, visual changes, or bleeding to a clinician.
• Vaccination status – Ensure up‑to‑date tetanus and influenza vaccines to reduce co‑infection risk.
• Work considerations – Discuss a gradual return‑to‑work plan with your employer; many patients resume full duties after 3‑4 weeks.

Prevention

Because the virus is vector‑borne, preventing mosquito exposure is key.

Individual Measures

• Use EPA‑registered insect repellents containing DEET (20‑30 %), picaridin, or oil of lemon eucalyptus.
• Wear long‑sleeved shirts and pants, especially during dawn and dusk when vectors are most active.
• Sleep under insecticide‑treated bed nets if the sleeping environment is not screened.
• Eliminate standing water around homes (empty containers, clean gutters, change water in pet dishes weekly).

Community & Public‑Health Actions

• Municipal larviciding programs targeting breeding sites.
• Community education campaigns—PDFs from WHO (2023) emphasize “source reduction” and personal protection.
• Surveillance reporting: health workers should notify local public‑health agencies of suspected cases promptly.

Complications

Although most infections are self‑limited, certain complications warrant attention:

• Severe hemorrhagic syndrome – Diffuse petechiae, mucosal bleeding, or gastrointestinal hemorrhage; can lead to hypovolemic shock.
• Neurologic involvement – Encephalitis, meningitis, or Guillain‑Barré–like polyneuropathy; may cause long‑term cognitive deficits.
• Chronic arthropathy – Persistent joint pain lasting > 6 months in ~10 % of adults.
• Pregnancy complications – Preterm labor and low birth weight have been reported anecdotally; data are limited.
• Secondary bacterial infection – Rare, usually follows skin breakdown from intense scratching of the rash.

When to Seek Emergency Care

References

• Mayo Clinic. “Dengue Fever” – comparative symptom chart. 2023.
• Centers for Disease Control and Prevention. “Guidelines for Diagnosis of Arboviral Diseases.” 2022.
• World Health Organization. “Vector‑borne diseases: Surveillance and control.” 2023.
• Cleveland Clinic. “Arthritis after viral infections.” 2022.
• Pan‑American Health Organization. “Emerging Bunyavirus Infections in the Americas.” 2024.

```